Celebrating the holidays and the 30th anniversary of the IMF

As we move into the holiday season, we are all looking forward to time with family and friends to enjoy, celebrate, and relax after a tumultuous year. This year was extraordinarily busy for the IMF, but in 2019 there were great steps forward to improve outcomes for myeloma patients everywhere. In last week’s blog, I summarized all the amazing details from the 2019 Annual Meeting of the American Society of Hematology (ASH). Those included the high expectations for the new immune therapies—CAR T-cell treatment, the new GlaxoSmithKline monoclonal antibody/drug conjugate, and bispecific antibodies that engage patients’ own T cells to fight myeloma.

Takeaways from ASH 2019

The IMF team just returned from an extremely busy and exciting meeting of the American Society of Hematology (ASH) in Orlando. What are the key takeaways from the myeloma research presented at this important event? Here is the news I found to be the most important.

ASH 2019 Update: Late-Breaking Abstracts and Hot-Topic Posters

Today, the American Society of Hematology (ASH) released late-breaking abstracts in advance of the 2019 ASH Annual Meeting, Dec. 7-10 in Orlando, Florida. 

Key early results from iStopMM project presented at 4th Annual Meeting in Reykjavik, Iceland

REYKJAVIK, Iceland, November 14, 2019—After three years of work, initial results from the IMF-supported iStopMM project were presented here today by Dr. Sigurdur Kristinsson (University of Iceland) and his team at the 4th annual iStopMM meeting. The acronym iStopMM stands for Iceland Screens, Treats, or Prevents Multiple Myeloma.

ASH Top 10 for 2019: Immune therapies again dominate the news

The American Society of Hematology (ASH) Annual Meeting will take place Dec. 7 through Dec. 10 in Orlando, Florida, and the abstracts for the meeting—always eagerly awaited—were released yesterday. Among the over 700 abstracts dealing with or mentioning myeloma, it is extremely difficult to highlight just 10 of interest. This year, 92 abstracts were selected for oral presentation and there is a clear preference for the high-profile, new, and emerging immune therapies, including CAR T-cell approaches. This should not distract from the huge poster sessions on Saturday, Dec. 7, Sunday, Dec. 8, and Monday, Dec. 9, which include numerous new and important reports. These will be a source of many “takeaways” from ASH when we have a chance to see full details. In the meantime, I will preview some of the top oral presentations which focus on new observations that may have an impact on the future of myeloma care.